Utah Medical Products, Inc.
Utah Medical Products, Inc. Fundamental Analysis
Utah Medical Products, Inc. (UTMD) shows moderate financial fundamentals with a PE ratio of 19.76, profit margin of 29.30%, and ROE of 9.56%. The company generates $0.0B in annual revenue with weak year-over-year growth of -18.56%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 41.0/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze UTMD's fundamental strength across five key dimensions:
Efficiency Score
WeakUTMD struggles to generate sufficient returns from assets.
Valuation Score
ExcellentUTMD trades at attractive valuation levels.
Growth Score
WeakUTMD faces weak or negative growth trends.
Financial Health Score
ExcellentUTMD maintains a strong and stable balance sheet.
Profitability Score
ModerateUTMD maintains healthy but balanced margins.
Key Financial Metrics
Is UTMD Expensive or Cheap?
P/E Ratio
UTMD trades at 19.76 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, UTMD's PEG of -7.66 indicates potential undervaluation.
Price to Book
The market values Utah Medical Products, Inc. at 1.87 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 18.08 times EBITDA. This signals the market has high growth expectations.
How Well Does UTMD Make Money?
Net Profit Margin
For every $100 in sales, Utah Medical Products, Inc. keeps $29.30 as profit after all expenses.
Operating Margin
Core operations generate 29.60 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $9.56 in profit for every $100 of shareholder equity.
ROA
Utah Medical Products, Inc. generates $9.21 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Utah Medical Products, Inc. generates strong operating cash flow of $10.85M, reflecting robust business health.
Free Cash Flow
Utah Medical Products, Inc. generates strong free cash flow of $10.60M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $3.31 in free cash annually.
FCF Yield
UTMD converts 5.08% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
19.76
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-7.66
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.87
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.60
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
37.62
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.10
vs 25 benchmark
How UTMD Stacks Against Its Sector Peers
| Metric | UTMD Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 19.76 | 29.28 | Better (Cheaper) |
| ROE | 9.56% | 820.00% | Weak |
| Net Margin | 29.30% | -19731.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 37.62 | 4.69 | Strong Liquidity |
| ROA | 9.21% | -17993.00% (disorted) | Weak |
UTMD outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Utah Medical Products, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-7.37%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
0.07%
Industry Style: Defensive, Growth, Innovation
GrowingFCF CAGR
-7.63%
Industry Style: Defensive, Growth, Innovation
Declining